Janssen - Glucose Regulation/Risp/Olanz
Schizophrenia, Type 2 Diabetes Mellitus
About this trial
This is an interventional treatment trial for Schizophrenia focused on measuring Schizophrenia, BMI, T2DM
Eligibility Criteria
Inclusion Criteria: Patients: meets DSM-IV criteria for schizophrenia, any type, or schizoaffective disorder; Aged 18 to 60 years; Able to give informed consent; No medication changes for 2 weeks prior to and during the period of study; 5. Patients: currently taking olanzapine, risperidone, haloperidol or another typical antipsychotic. Exclusion Criteria: Controls: Axis I psychiatric disorder criteria met except for substance use disorders as below; Meets DSM-IV criteria for the diagnoses of substance abuse or dependence within the past six months; Involuntary legal status (as per Missouri law); The presence of any serious medical disorder that may (as confirmed by peer-reviewed literature) confound the assessment of symptoms, relevant biologic measures or diagnosis; the following conditions are currently identified: insulin- or non-insulin-dependent diabetes mellitus; any intra-abdominal or intrathoracic surgery or limb amputation within the prior 6 months; any diagnosed cardiac condition causing documented hemodynamic compromise; any diagnosed respiratory condition causing documented or clinically recognized hypoxia; pregnancy or high dose estrogens, fever, narcotic therapy, acute sedative hypnotic withdrawal, corticosteroid or spironolactone therapy, dehydration, epilepsy, endocrine disease, high-dose benzodiazepine therapy (> 25 mg/day of diazepam), or any medical condition known to interfere with glucose utilization; Meets DSM-IV criteria for Mental Retardation (mild or worse).
Sites / Locations
- Washington University School of Medicine, Psychiatry Dept.